TTK Healthcare Limited

NSE:TTKHLTCARE India Drug Manufacturers - General
Market Cap
$138.26 Million
₹11.97 Billion INR
Market Cap Rank
#23312 Global
#1213 in India
Share Price
₹847.40
Change (1 day)
-0.87%
52-Week Range
₹847.40 - ₹1366.90
All Time High
₹1843.10
About

TTK Healthcare Limited engages in the animal welfare, consumer product, medical device, protective device, food, and other businesses in India. It operates through Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods, and Others segments. The Animal Welfare segment offers various feed supplements, liver correctives, fertility inducers, antibiotics, antiparasiticides, anti… Read more

TTK Healthcare Limited (TTKHLTCARE) - Net Assets

Latest net assets as of September 2025: ₹10.85 Billion INR

Based on the latest financial reports, TTK Healthcare Limited (TTKHLTCARE) has net assets worth ₹10.85 Billion INR as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹12.96 Billion) and total liabilities (₹2.10 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets ₹10.85 Billion
% of Total Assets 83.75%
Annual Growth Rate 18.44%
5-Year Change 261.47%
10-Year Change 681.9%
Growth Volatility 40.04

TTK Healthcare Limited - Net Assets Trend (2005–2025)

This chart illustrates how TTK Healthcare Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for TTK Healthcare Limited (2005–2025)

The table below shows the annual net assets of TTK Healthcare Limited from 2005 to 2025.

Year Net Assets Change
2025-03-31 ₹10.65 Billion +6.41%
2024-03-31 ₹10.01 Billion +4.99%
2023-03-31 ₹9.53 Billion +189.23%
2022-03-31 ₹3.30 Billion +11.87%
2021-03-31 ₹2.95 Billion +18.34%
2020-03-31 ₹2.49 Billion -0.97%
2019-03-31 ₹2.51 Billion +7.92%
2018-03-31 ₹2.33 Billion +54.46%
2017-03-31 ₹1.51 Billion +10.73%
2016-03-31 ₹1.36 Billion +15.17%
2015-03-31 ₹1.18 Billion +10.61%
2014-03-31 ₹1.07 Billion +8.86%
2013-03-31 ₹982.22 Million +11.99%
2012-03-31 ₹877.03 Million +15.80%
2011-03-31 ₹757.35 Million +17.10%
2010-03-31 ₹646.73 Million +4.15%
2009-03-31 ₹620.96 Million +8.33%
2008-03-31 ₹573.23 Million +19.34%
2007-03-31 ₹480.31 Million +31.58%
2006-03-31 ₹365.03 Million +1.21%
2005-03-31 ₹360.68 Million --

Equity Component Analysis

This analysis shows how different components contribute to TTK Healthcare Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 3091.5% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component Amount Percentage
Retained Earnings ₹9.40 Billion 88.27%
Common Stock ₹141.30 Million 1.33%
Other Comprehensive Income ₹1.01 Billion 9.48%
Other Components ₹98.25 Million 0.92%
Total Equity ₹10.65 Billion 100.00%

TTK Healthcare Limited Competitors by Market Cap

The table below lists competitors of TTK Healthcare Limited ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in TTK Healthcare Limited's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 10,009,189,000 to 10,650,482,000, a change of 641,293,000 (6.4%).
  • Net income of 816,569,000 contributed positively to equity growth.
  • Dividend payments of 141,303,000 reduced retained earnings.
  • Other comprehensive income decreased equity by 13,846,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income ₹816.57 Million +7.67%
Dividends Paid ₹141.30 Million -1.33%
Other Comprehensive Income ₹-13.85 Million -0.13%
Other Changes ₹-20.13 Million -0.19%
Total Change ₹- 6.41%

Book Value vs Market Value Analysis

This analysis compares TTK Healthcare Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.12x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 33.17x to 1.12x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2005-03-31 ₹25.54 ₹847.40 x
2006-03-31 ₹25.85 ₹847.40 x
2007-03-31 ₹34.02 ₹847.40 x
2008-03-31 ₹40.60 ₹847.40 x
2009-03-31 ₹43.98 ₹847.40 x
2010-03-31 ₹45.80 ₹847.40 x
2011-03-31 ₹53.64 ₹847.40 x
2012-03-31 ₹62.11 ₹847.40 x
2013-03-31 ₹69.56 ₹847.40 x
2014-03-31 ₹75.73 ₹847.40 x
2015-03-31 ₹83.76 ₹847.40 x
2016-03-31 ₹96.47 ₹847.40 x
2017-03-31 ₹106.82 ₹847.40 x
2018-03-31 ₹164.88 ₹847.40 x
2019-03-31 ₹177.94 ₹847.40 x
2020-03-31 ₹176.22 ₹847.40 x
2021-03-31 ₹208.53 ₹847.40 x
2022-03-31 ₹233.28 ₹847.40 x
2023-03-31 ₹674.72 ₹847.40 x
2024-03-31 ₹708.36 ₹847.40 x
2025-03-31 ₹753.75 ₹847.40 x

Capital Efficiency Dashboard

This dashboard shows how efficiently TTK Healthcare Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 7.67%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 9.36%
  • • Asset Turnover: 0.68x
  • • Equity Multiplier: 1.20x
  • Recent ROE (7.67%) is below the historical average (13.92%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2005 -5.74% -1.35% 1.65x 2.58x ₹-56.77 Million
2006 5.49% 1.07% 2.04x 2.51x ₹-16.47 Million
2007 6.25% 1.42% 2.05x 2.15x ₹-18.02 Million
2008 21.26% 6.12% 1.67x 2.08x ₹64.56 Million
2009 12.68% 3.59% 1.59x 2.22x ₹16.65 Million
2010 14.11% 3.62% 1.63x 2.39x ₹26.60 Million
2011 19.44% 4.74% 1.60x 2.55x ₹71.48 Million
2012 17.82% 4.42% 1.66x 2.43x ₹68.59 Million
2013 14.46% 3.72% 1.82x 2.13x ₹43.81 Million
2014 11.59% 2.98% 1.73x 2.24x ₹16.96 Million
2015 13.66% 3.35% 1.75x 2.33x ₹43.28 Million
2016 16.64% 4.40% 1.70x 2.22x ₹90.44 Million
2017 12.82% 3.65% 1.85x 1.90x ₹42.50 Million
2018 7.80% 3.15% 1.41x 1.75x ₹-51.32 Million
2019 9.69% 3.89% 1.51x 1.65x ₹-7.69 Million
2020 4.95% 1.91% 1.49x 1.73x ₹-125.80 Million
2021 15.76% 9.76% 0.96x 1.68x ₹169.76 Million
2022 12.62% 6.94% 1.07x 1.69x ₹86.25 Million
2023 67.10% 88.22% 0.62x 1.23x ₹5.44 Billion
2024 6.28% 8.41% 0.62x 1.20x ₹-372.50 Million
2025 7.67% 9.36% 0.68x 1.20x ₹-248.48 Million

Industry Comparison

This section compares TTK Healthcare Limited's net assets metrics with peer companies in the Drug Manufacturers - General industry.

Industry Context

  • Industry: Drug Manufacturers - General
  • Average net assets among peers: $6,446,430,401
  • Average return on equity (ROE) among peers: 24.45%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
TTK Healthcare Limited (TTKHLTCARE) ₹10.85 Billion -5.74% 0.19x $31.85 Million
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) $16.96 Billion 22.18% 0.80x $1.19 Billion
Kopran Limited (KOPRAN) $1.09 Billion 9.86% 1.43x $34.19 Million
Marksans Pharma Limited (MARKSANS) $9.05 Billion 26.35% 0.36x $428.52 Million
NGL Fine-Chem Limited (NGLFINE) $160.59 Million 15.04% 1.05x $39.88 Million
Pfizer Limited (PFIZER) $9.01 Billion 33.25% 0.22x $818.67 Million
Sanofi India Limited (SANOFI) $17.36 Billion 17.53% 0.46x $376.73 Million
SANOFI CONS HEALTHC IND L (SANOFICONR) $2.08 Billion 79.43% 0.66x $324.08 Million
SENORES PHARMACEUTICALS L (SENORES) $94.96 Million 7.21% 0.53x $157.65 Million
SMS Pharmaceuticals Limited (SMSPHARMA) $2.22 Billion 9.19% 1.30x $105.56 Million